Development of an Abbott ARCHITECT cyclosporine immunoassay without metabolite cross-reactivity.
Clin Biochem
; 43(13-14): 1152-7, 2010 Sep.
Article
em En
| MEDLINE
| ID: mdl-20599875
ABSTRACT
OBJECTIVE:
We investigated the mechanism by which the ARCHITECT cyclosporine (CsA) chemiluminescent microparticle immunoassay (CMIA) eliminates cross-reactivity to CsA metabolites AM1 and AM9, despite its use of a monoclonal antibody which shows cross-reactivity in fluorescence polarization immunoassays. DESIGN ANDMETHODS:
The CMIA was accomplished by incubating an extracted blood sample with magnetic microparticles coated with a very low amount of anti-CsA antibody. After a wash step the microparticles were incubated with a chemiluminescent CsA tracer, followed by a second wash step and measurement of chemiluminescence. The reagent concentrations of salt and detergent were optimized to maximize CsA binding and minimize metabolite interference.RESULTS:
Elimination of CsA metabolite cross-reactivity was shown using purified metabolites and blood samples containing native CsA metabolites. The CMIA demonstrated precision and sensitivity acceptable for use in a clinical setting.CONCLUSION:
We conclude that it is possible to eliminate CsA metabolite immuno-cross-reactivity by careful assay design.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Imunoensaio
/
Ciclosporina
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Biochem
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Estados Unidos